B-cell maturation antigen-Targeted T-cell Engager Therapy Combined with B cell Depletion for Treatment of Refractory HLA Sensitization - PubMed
7 days ago
- #BCMA-targeted therapy
- #HLA desensitization
- #Kidney transplantation
- B-cell maturation antigen (BCMA)-targeted T-cell engager therapy combined with B cell depletion was used to treat refractory HLA sensitization.
- A 37-year-old woman with extreme HLA sensitization (cPRA >99.9%) and kidney failure was treated with obinutuzumab (anti-CD20) and elranatamab (BCMA-targeted T-cell engager).
- The therapy resulted in a profound reduction of anti-HLA antibodies, decreasing cPRA from 99.96% to 0% within six months.
- The patient underwent successful kidney transplantation without rejection and maintained excellent graft function at ten months post-transplant.
- This dual-agent strategy represents a promising approach for patients with prohibitive HLA sensitization.